Curis, Inc. ( NASDAQ: CRIS) Cantor Global Healthcare Conference 2025 September 5, 2025 9:45 AM EDT ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 ...

Nurix Therapeutics, Inc. ( NASDAQ: NRIX) Baird Global Healthcare Conference 2025 September 9, 2025 10:50 AM EDT ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that met all primary and co-primary endpoints. Th ...

MRI decoding reveals that the inferior frontal junction-visual network reinstates target-related information as a proxy for target localization before visual search.

Johnson & Johnson has also initiated the Phase 3 ICONIC-ASCEND f study, the first head-to-head study seeking to demonstrate the superiority of an oral tablet, icotrokinra, compared to an injectable ...